Researchers discover unexpected role of an immune system receptor; blocking it halts human cancer cell growth and improves survival in animal models
For some cancers, initial treatment with chemotherapy brings positive, but only temporary, results: tumors shrink, but then rebound as the cancer becomes drug-resistant. This pattern of remission-resistance-relapse is particularly true for pancreatic cancer, an aggressive disease in which early success is often countered by eventual disease progression.
To wit: The one-year relative survival rate for pancreatic cancer is 20 percent, according to the American Cancer Society. The five-year rate is just 7 percent.
The reason: Current multidrug chemotherapy regimens targeting pancreatic cancer typically do not fully eradicate all cancer cells, leaving behind drug-resistant cells that harbor aberrant stem cell properties and can drive tumor regrowth and metastasis.
In a new paper publishing in the April 4, 2019 online issue of Cell, an international team of scientists led by researchers at University of California San Diego School of Medicine employed an array of next-generation sequencing and gene-editing tools, such as CRISPR, to map the molecular dependencies —and thus vulnerabilities — of pancreatic cancer stem cells.
Most notably, they found that a key hormone receptor called retinoic acid receptor-related orphan receptor gamma or ROR?, previously studied in inflammation and T-cell differentiation, was especially active during pancreatic cancer progression, and that blocking it markedly slowed patient derived tumor growth and improved survival in animal models.
“These studies revealed an unexpected role for immuno-regulatory genes in the maintenance of the most aggressive, drug-resistant cells in pancreatic cancer,” said senior study author Tannishtha Reya, PhD, UC San Diego professor in the departments of Pharmacology and Medicine. In particular, ROR? emerged as a key regulator. ROR? rose with cancer progression and its inhibition through genetic and pharmacological approaches resulted in a striking defect in pancreatic cancer growth.
“Our work shows that immune system signals are hijacked by pancreatic cancer, and suggests that therapies currently being tested for autoimmune indications should be considered for testing in pancreatic cancer,” said Reya.
Using genome scale approaches to map stem cell dependencies in pancreatic cancer “will be invaluable for understanding the basis of therapy resistance and recurrence and for discovering new vulnerabilities in pancreatic cancer,” said Reya. “Beyond providing new scientific insight, this work can help identify pathways for which clinical grade inhibitors may already exist and can thus be rapidly tested in pancreatic cancer.”
In particular, she said the discovery of ROR?‘s role in promoting tumor growth provides a new avenue for research and potential therapies. “One exciting aspect is the possibility that nuclear hormone receptors could represent therapeutic targets for pancreatic cancer. In fact, drugs targeting ROR? have already been developed by several pharmaceutical companies, and are in trials for autoimmune diseases. Our findings suggest that these agents could also be a valuable therapeutic strategy for pancreatic cancer.”
Learn more: Genome-Wide Analysis Reveals New Strategies to Target Pancreatic Cancer
The Latest on: Pancreatic cancer
[google_news title=”” keyword=”pancreatic cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pancreatic cancer
- USA News Group: Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatmenton May 17, 2024 at 10:01 am
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 17, 2024 /PRNewswire/ -- USA News Group - A new study is bringing hope in the fight against one of the deadliest cancers, revealing a ...
- Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatmentson May 17, 2024 at 8:49 am
A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough is crucial, as ...
- Gimatecan by Lee’s Pharmaceutical for Metastatic Pancreatic Cancer: Likelihood of Approvalon May 16, 2024 at 7:20 pm
Gimatecan is under clinical development by Lee's Pharmaceutical and currently in Phase II for Metastatic Pancreatic Cancer.
- Blacks Have The Highest Rates of Pancreatic Cancer, But We’re Missing From Pancreatic Cancer Trialson May 16, 2024 at 11:04 am
New research from Indiana University shows that Black Americans have higher incidence of pancreatic cancer but aren't receiving enough treatment.
- Ashland man battles stage four pancreatic cancer with family, faith, and local careon May 16, 2024 at 3:27 am
Scott Montgomery has had his share of health scares, including surviving an accidental gunshot wound and living for more than a decade with multiple sclerosis.N ...
- Biotech Innovations Drive Hope In Global Fight Against Pancreatic Canceron May 15, 2024 at 10:28 am
WISA Surges on News NYCB Surges on Loan Sale AMC Gulches on Meme Stock Collapse Lithium's Future Looks Bright: Demand ...
- Questions About Pancreatic Cancer? Harvard Health Publishing Has Answers.on May 13, 2024 at 2:28 pm
What are the reasons for pancreatic cancer? Answered by Dr. Howard E. Lewine M.D. Chief Medical Editor, Harvard Health Publishing · 40 years of experience · USA For most types of pancreatic cancer, ...
- Big boost for cancer researchon May 11, 2024 at 1:59 am
Now, Gov. Kathy Hochul has boosted the effort to combat this disease by having the state contribute $15 million toward the Cold Spring Harbor center, which also receives funds from the Lustgarten ...
- Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Canceron May 9, 2024 at 12:16 pm
Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially ...
- Cold Spring Harbor Lab wins $15 million from NYS for pancreatic cancer researchon May 4, 2024 at 4:08 am
The state will put $15 million toward a $30 million research center at Cold Spring Harbor Laboratory for pancreatic cancer, a disease that is fatal for most people, Gov. Kathy Hochul told Newsday on ...
via Bing News